Meeting of the immunization Strategic Advisory Group of Experts, Geneva, 10-11 April 2006: conclusions and recommendations.
D000962:Antimalarials / Q000627:therapeutic use; D002648:Child; D003140:Communicable Disease Control / Q000191:economics / Q000458:organization & administration; D004672:Encephalitis, Japanese / Q000517:prevention & control; D014943:Global Health; D006292:Health Priorities; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D053124:Influenza A Virus, H5N1 Subtype; D007252:Influenza Vaccines / Q000600:supply & distribution; D022321:Japanese Encephalitis Vaccines / Q000627:therapeutic use; D008288:Malaria / Q000517:prevention & control; D032541:Mass Vaccination / Q000191:economics; D008457:Measles / Q000401:mortality / Q000517:prevention & control; D008458:Measles Vaccine / Q000627:therapeutic use; D009107:Mumps / Q000517:prevention & control; D009108:Mumps Vaccine / Q000627:therapeutic use; D011008:Pneumococcal Infections / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000627:therapeutic use; D013742:Tetanus / Q000517:prevention & control; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000627:therapeutic use; D014611:Vaccination / Q000191:economics; D014944:World Health Organization
D000962:Antimalarials; D007252:Influenza Vaccines; D022321:Japanese Encephalitis Vaccines; D008458:Measles Vaccine; D009108:Mumps Vaccine; D022242:Pneumococcal Vaccines; D013745:Tetanus Toxoid